By Value 7.2
Eligibility is individual
3: KPV Proposed use: Wound healing and inflammatory condition Proposed forms: Cream and gel No
Room temperature exposure should not exceed 1 week for lyophilized fragment peptides
With the compounded GLP-1 market becoming increasingly competitive, pharmacies differentiate their products by adding value-added ingredients

otherwise 100,- Zone 1 (EU) including Switzerland and United Kingdom (GB): Belgium, Bulgaria, Denmark (except Faroe Islands, Greenland), Estonia, Finland (except land Islands), France (except overseas territories and departments), Greece (except Mount Athos), United Kingdom (GB, except Channel Islands), Ireland, Italy (except Livigno and Campione d'Italia), Croatia, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands (except non-European territories), Austria, Poland, Portugal, Romania, Sweden, Slovakia, Slovenia, Spain (except Canary Islands, Ceuta + Melilla), Czech Republic, Hungary, Cyprus/Republic (except northern part), including Switzerland Zone 2 (Europe excluding the EU): land Islands (Finland), Andorra, Albania, Armenia, Azerbaijan, Mount Athos (GR), Bosnia and Herzegovina, Campione d'Italia (IT), Ceuta (E), Faroe Islands (DK), Georgia, Gibraltar (GB), Greenland (DK), Guernsey (GB), Iceland, Jersey (GB), Canary Islands (E), Kazakhstan , Kosovo (Serbian province), Liechtenstein, Livigno (IT), Macedonia, Melilla (E), Moldova (Republic), Montenegro (Republic), Norway, Russian Federation, San Marino, Serbia (Republic), Turkey, Ukraine, Vatican City, Belarus, Cyprus/Republic (northern part) Zone 3 (World): Egypt, Algeria, Bahrain, Iran, Iraq, Israel, Yemen, Jordan, Canada, Qatar, Kuwait, Lebanon, Libya, Morocco, Oman, Saudi Arabia, Syria Tunisia, USA, United Arab Emirates Zone 4 (Rest of the world): All countries and territories not assigned to Zones 1, 2 or 3
